Floatz logo

Trilaciclib

CDK4/6-dependent Solid Tumors

Hebei Medical University Fourth HospitalSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the CDK4/6-dependent Solid Tumors cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Trilaciclib is also rated in:

small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
myelosuppression, non-human animalDormant
B
Indicative ·
60 / 100
View asset →
Myelosuppression-AdultDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →